QCI Asset Management Inc. NY continued to hold its stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 710 shares of the medical instruments supplier’s stock at the close of the 2nd quarter. QCI Asset Management Inc. NY’s holdings in Becton, Dickinson and were worth $139,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Almanack Investment Partners LLC. acquired a new stake in shares of Becton, Dickinson and during the 1st quarter worth approximately $105,000. Parkside Financial Bank & Trust grew its holdings in shares of Becton, Dickinson and by 1.4% during the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 9 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares in the last quarter. Financial Architects Inc grew its holdings in shares of Becton, Dickinson and by 8.0% during the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after purchasing an additional 54 shares in the last quarter. Finally, Guardian Life Insurance Co. of America grew its holdings in shares of Becton, Dickinson and by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 6 shares in the last quarter. 87.12% of the stock is currently owned by institutional investors.

Shares of Becton, Dickinson and Company (BDX) opened at 194.05 on Thursday. The company has a 50-day moving average price of $199.01 and a 200-day moving average price of $191.58. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The company has a market cap of $44.16 billion, a P/E ratio of 56.20 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same period last year, the company earned $2.35 EPS. On average, analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.50%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

Several analysts recently commented on BDX shares. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a research note on Monday, July 17th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $200.93.

In other news, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the transaction, the insider now directly owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is owned by corporate insiders.

WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/28/qci-asset-management-inc-ny-holds-holdings-in-becton-dickinson-and-company-bdx.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.